158 related articles for article (PubMed ID: 24360556)
1. Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.
Duveau DY; Yasgar A; Wang Y; Hu X; Kouznetsova J; Brimacombe KR; Jadhav A; Simeonov A; Thomas CJ; Maloney DJ
Bioorg Med Chem Lett; 2014 Jan; 24(2):630-5. PubMed ID: 24360556
[TBL] [Abstract][Full Text] [Related]
2. High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships.
Niesen FH; Schultz L; Jadhav A; Bhatia C; Guo K; Maloney DJ; Pilka ES; Wang M; Oppermann U; Heightman TD; Simeonov A
PLoS One; 2010 Nov; 5(11):e13719. PubMed ID: 21072165
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones as a novel class of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.
Cho H; Tai HH
Arch Biochem Biophys; 2002 Sep; 405(2):247-51. PubMed ID: 12220539
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents.
Cho H; Tai HH
Prostaglandins Leukot Essent Fatty Acids; 2002 Dec; 67(6):461-5. PubMed ID: 12468268
[TBL] [Abstract][Full Text] [Related]
5. Control of the intracellular levels of prostaglandin E₂ through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing.
Choi D; Piao YL; Wu Y; Cho H
Bioorg Med Chem; 2013 Aug; 21(15):4477-84. PubMed ID: 23791868
[TBL] [Abstract][Full Text] [Related]
6. Lipopolysaccharide-induced murine embryonic resorption involves nitric oxide-mediated inhibition of the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase.
Aisemberg J; Bariani MV; Vercelli CA; Wolfson ML; Franchi AM
Reproduction; 2012 Oct; 144(4):447-54. PubMed ID: 22843771
[TBL] [Abstract][Full Text] [Related]
7. The wound-healing effect of 7,3',4'-trimethoxyflavone through increased levels of prostaglandin E
Sun KH; Karna S; Moon YS; Cho H; Choi CH
Biotechnol Lett; 2017 Oct; 39(10):1575-1582. PubMed ID: 28664315
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
Antczak MI; Zhang Y; Wang C; Doran J; Naidoo J; Voruganti S; Williams NS; Markowitz SD; Ready JM
J Med Chem; 2017 May; 60(9):3979-4001. PubMed ID: 28398755
[TBL] [Abstract][Full Text] [Related]
9. Understanding human 15-hydroxyprostaglandin dehydrogenase binding with NAD+ and PGE2 by homology modeling, docking and molecular dynamics simulation.
Hamza A; Cho H; Tai HH; Zhan CG
Bioorg Med Chem; 2005 Jul; 13(14):4544-51. PubMed ID: 15908215
[TBL] [Abstract][Full Text] [Related]
10. Wound healing effects of new 15-hydroxyprostaglandin dehydrogenase inhibitors.
Piao YL; Seo SY; Lim SC; Cho H
Prostaglandins Leukot Essent Fatty Acids; 2014 Dec; 91(6):325-32. PubMed ID: 25458900
[TBL] [Abstract][Full Text] [Related]
11. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Ding Y; Tong M; Liu S; Moscow JA; Tai HH
Carcinogenesis; 2005 Jan; 26(1):65-72. PubMed ID: 15358636
[TBL] [Abstract][Full Text] [Related]
12. ROS-Mediated 15-Hydroxyprostaglandin Dehydrogenase Degradation via Cysteine Oxidation Promotes NAD
Wang W; Hu Y; Wang X; Wang Q; Deng H
Cell Chem Biol; 2018 Mar; 25(3):255-261.e4. PubMed ID: 29307841
[TBL] [Abstract][Full Text] [Related]
13. Studies on 15-hydroxyprostaglandin dehydrogenase with various prostaglandin analogues.
Ohno H; Morikawa Y; Hirata F
J Biochem; 1978 Dec; 84(6):1485-94. PubMed ID: 216666
[TBL] [Abstract][Full Text] [Related]
14. 15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy.
Na HK; Park JM; Lee HG; Lee HN; Myung SJ; Surh YJ
Biochem Pharmacol; 2011 Nov; 82(10):1352-60. PubMed ID: 21856294
[TBL] [Abstract][Full Text] [Related]
15. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
Otani T; Yamaguchi K; Scherl E; Du B; Tai HH; Greifer M; Petrovic L; Daikoku T; Dey SK; Subbaramaiah K; Dannenberg AJ
Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G361-8. PubMed ID: 16195422
[TBL] [Abstract][Full Text] [Related]
16. C-Terminal region of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase is involved in the interaction with prostaglandin substrates.
Zhou H; Yan F; Tai HH
Eur J Biochem; 2001 Jun; 268(12):3368-74. PubMed ID: 11422365
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors.
Wu Y; Karna S; Choi CH; Tong M; Tai HH; Na DH; Jang CH; Cho H
J Med Chem; 2011 Jul; 54(14):5260-4. PubMed ID: 21650226
[TBL] [Abstract][Full Text] [Related]
18. A 15-hydroxyprostaglandin dehydrogenase specific for prostaglandin A in rabbit kidney.
Oien HG; Ham EA; Zanetti ME; Ulm EH; Kuehl FA
Proc Natl Acad Sci U S A; 1976 Apr; 73(4):1107-11. PubMed ID: 4794
[TBL] [Abstract][Full Text] [Related]
19. Local modulation by 11beta-hydroxysteroid dehydrogenase of glucocorticoid effects on the activity of 15-hydroxyprostaglandin dehydrogenase in human chorion and placental trophoblast cells.
Patel FA; Sun K; Challis JR
J Clin Endocrinol Metab; 1999 Feb; 84(2):395-400. PubMed ID: 10022390
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
